Protalix BioTherapeutics
PLX
45 hedge funds and large institutions have $8.4M invested in Protalix BioTherapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 8 closing their positions.
880% more call options, than puts
Call options by funds: $98K | Put options by funds: $10K
138% more capital invested
Capital invested by funds: $3.53M → $8.4M (+$4.87M)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
1.3% more ownership
Funds ownership: 4.67% → 5.97% (+1.3%)
0% more funds holding
Funds holding: 45 → 45 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$961K |
| 2 |
Renaissance Technologies
New York
|
+$229K |
| 3 |
Morgan Stanley
New York
|
+$180K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$144K |
| 5 |
Jane Street
New York
|
+$95.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$183K |
| 2 |
OGF
Orin Green Financial
San Diego,
California
|
-$102K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.2K |
| 4 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
-$62.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$35.8K |
PLX Hedge Fund Activity: Q4 2024 in Review
45 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2024, worth a combined $8.4M — up 138% from $3.53M a quarter earlier.
Fund positioning in PLX was balanced in Q4 2024: 8 funds opened new positions, 8 closed out, 12 added to existing stakes and 8 trimmed.
The largest buyer was Northern Trust, adding an estimated $961K. The largest seller was GSA Capital Partners, cutting an estimated $183K.
- 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $8.4M of Protalix BioTherapeutics stock for Q4 2024, up 138% quarter-over-quarter.
- 8 funds opened new Protalix BioTherapeutics positions in Q4 2024 and 8 closed out, a net change of 0 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2024 was Northern Trust, an estimated $961K added.
- The largest Protalix BioTherapeutics seller in Q4 2024 was GSA Capital Partners, an estimated $183K sold.
Based on aggregated 13F filings for Q4 2024.